KPV (Lys-Pro-Val)

Also: Lys-Pro-Val, Lysine-Proline-Valine, α-MSH(11-13), KPV tripeptide

Melanocortin-derived tripeptidePreliminaryStudied primarily in preclinical settings (in-vitro assays and animal models); publicly available human clinical evidence is sparse. KPV is discussed and distributed as a research-use-only compound and is not an approved drug. Mechanistic interpretation and any extrapolation to human or animal outcomes require independent editorial and source verification.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

KPV is a synthetic tripeptide (lysine-proline-valine) that corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). It is discussed in the research literature primarily in the context of mechanisms reported as anti-inflammatory in in-vitro and animal models. Publicly available human clinical evidence is limited, and findings should be interpreted cautiously given the preclinical nature of most studies and known translation limitations. KPV is handled as a research-use-only compound and is not an approved therapy for any use.

Mechanism as described in the literature

KPV is a synthetic tripeptide (Lys-Pro-Val) that corresponds to the C-terminal three amino acids of alpha-melanocyte-stimulating hormone (α-MSH). Because it shares this sequence, it is studied within the broader context of melanocortin-derived peptide biology rather than as a distinct receptor-defined drug class.

In-vitro studies have reported effects characterized as anti-inflammatory, with proposed mechanisms including interference with pro-inflammatory signaling pathways (for example NF-κB) and modulation of immune and epithelial cell responses. Some reports describe activity that does not appear to require classical melanocortin receptors, which has prompted discussion of possible intracellular sites of action. These observations are drawn largely from cell-culture and animal models, and their relevance to humans remains uncertain and unverified.

Research areas

Inflammatory signaling modulation (e.g., NF-κB pathway) described in vitro
Intestinal and mucosal inflammation in animal models
Melanocortin-derived peptide biology and structure-activity relationships
Epithelial and immune cell responses in cell-culture systems
Reported antimicrobial activity in laboratory assays

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is KPV?+

KPV is a synthetic tripeptide composed of lysine, proline, and valine (Lys-Pro-Val). It corresponds to the C-terminal fragment of the larger signaling peptide alpha-melanocyte-stimulating hormone (α-MSH) and is handled as a research compound.

What does the research literature focus on?+

Published work largely examines mechanisms reported as anti-inflammatory in cell-culture and animal models, including effects on pro-inflammatory signaling pathways. These are mechanistic, preclinical observations and do not establish any benefit in humans.

Is KPV approved or proven for any use?+

No. KPV is an unapproved, research-use-only compound. The available evidence is predominantly preclinical, and KPV has not been established as safe or effective for any human or animal application.